Differences in biomarkers and molecular pathways according to age for patients with HFrEF.
Age Factors
Aged
Aged, 80 and over
Biomarkers
/ blood
Europe
Female
Heart Failure, Systolic
/ blood
Humans
Male
Middle Aged
Predictive Value of Tests
Prognosis
Protein Interaction Maps
Proteome
Proteomics
Reproducibility of Results
Risk Assessment
Risk Factors
Stroke Volume
Ventricular Function, Left
Ageing
Biological age
Biomarkers
Chronological age
Heart failure with reduced ejection fraction
Journal
Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427
Informations de publication
Date de publication:
29 08 2021
29 08 2021
Historique:
received:
29
05
2020
revised:
21
08
2020
accepted:
17
09
2020
pubmed:
2
10
2020
medline:
25
2
2022
entrez:
1
10
2020
Statut:
ppublish
Résumé
Elderly patients with heart failure with reduced ejection fraction (HFrEF) have worse prognosis and less often receive guideline-recommended therapies. We aim to better understand the underlying pathophysiological processes associated with ageing in HFrEF potentially leading to targeted therapies in this vulnerable population. From a panel of 363 cardiovascular biomarkers available in 1611 patients with HFrEF in the BIOSTAT-CHF index cohort and cross-validated in 823 patients in the BIOSTAT-CHF validation cohort, we tested which biomarkers were dysregulated in patients aged >75 vs. <65 years. Second, pathway overrepresentation analyses were performed to identify biological pathways linked to higher plasma concentrations of biomarkers in elderly vs. younger patients. After adjustment, multiple test correction [false discovery rate (FDR) 1%], and cross-validation, 27/363 biomarkers were associated with older age, 22 positively and 5 negatively. The biomarkers that were positively associated with older age were associated with tumour cell regulation, extra-cellular matrix organization, and inflammatory processes, whereas biomarkers negatively associated with older age were associated with pathways that may point to cell proliferation and tumourigenesis. Among the 27 biomarkers, WFDC2 (WAP four-disulphide core domain protein 2)-that broadly functions as a protease inhibitor-was associated with older age and had the strongest association with all outcomes. No protein-by-sex interaction was observed. In elderly HFrEF patients, pathways associated with extra-cellular matrix organization, inflammatory processes, and tumour cell regulation were activated, while pathways associated with tumour proliferation functions were down-regulated. These findings may help in a better understanding of the ageing processes in HFrEF and identify potential therapeutic targets.
Identifiants
pubmed: 33002110
pii: 5917017
doi: 10.1093/cvr/cvaa279
doi:
Substances chimiques
Biomarkers
0
Proteome
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2228-2236Subventions
Organisme : European Commission
ID : FP7-242209-BIOSTAT-CHF
Organisme : Roche Diagnostics
Organisme : French PIA project 'Lorraine Université d'Excellence' GEENAGE
ID : ANR-15-IDEX-04-LUE
Organisme : European Research Council (ERC
ID : CoG 818715
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.